Loading news...
The U.S. Food and Drug Administration said on Friday it has notified manufacturers of certain Parkinson's disease treatments to update their prescribing information with a new warning about a potential risk of seizures.
Amneal Pharmaceuticals, Inc. remains a Buy, with 45-55% upside potential and a $5-6bn market cap target in my opinion. AMRX delivered strong 2025 results—revenue up to $3.02bn, operating income $421m, and net leverage reduced to 3.5x. 2026 guidance is mixed: 1-4% revenue growth, but 5-10% adjusted EBITDA and 12-24% EPS growth, with division performance diverging.
Amneal Pharmaceuticals, Inc. (AMRX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
ECG, AMRX, NESR, ACMR and HSY have been added to the Zacks Rank #1 (Strong Buy) List on March 9th, 2026.
AMRX, VET and NESR made it to the Zacks Rank #1 (Strong Buy) value stocks list on March 9th, 2026.
BRIDGEWATER, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Executive and President, will participate in a fireside chat at the following upcoming investor conference:
Amneal Pharmaceuticals (NASDAQ: AMRX) reported fourth-quarter and full-year 2025 results and outlined its 2026 outlook, highlighting growth across the business, expanding complex product launches, and continued investment in specialty brands, biosimilars, and GLP-1 manufacturing capacity. 2025 results: revenue growth and margin expansion Co-CEO Chirag Patel said 2025 was a "defining year" marked by execution and portfolio
While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amneal Pharmaceuticals, Inc. (AMRX) Q4 2025 Earnings Call Transcript
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.12 per share a year ago.
‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q4 2025 Net Revenue of $814 million ; GAAP Net Income of $35 million ; Diluted Income per Share of $0.11 ‒ ‒ Q4 2025 Adjusted Net Income of $68 million , Adjusted EBITDA of $175 million ; Adjusted Diluted EPS of $0.21 ‒ ‒ Full Year 2025 Net Revenue of $3.02 billion ; GAAP Net Income of $72 million ; Diluted Income per Share of $0.22 ‒ ‒ Full Year 2025 Adjusted Net Income of $269 million ; Adjusted EBITDA of $688 million ; Adjusted Diluted EPS of $0.83 ‒ ‒ Provides 2026 Financial Guidance of $3.05 to $3.15 billion in net revenue, $720 to $760 million in Adjusted EBITDA, and $0.93 to $1.03 in Adjusted Diluted EPS – BRIDGEWATER, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the fourth quarter and full year ended December 31, 2025.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Shares of Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five research firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The
/PRNewswire/ -- Equity-Insider.com News Commentary - The global health and wellness sector is entering 2026 on a trajectory toward $6 trillion in annual
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
BRIDGEWATER, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been added to the S&P SmallCap 600® Index.
Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE: CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent SM Energy Co. (NYSE: SM) is acquiring Civitas Resources in a deal expected to be completed soon, pending final closing conditions.
BRIDGEWATER, N.J., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to market open. The Company will host an audio webcast at 8:30 a.m. ET.
Here is how Amneal Pharmaceuticals (AMRX) and Biohaven Ltd. (BHVN) have performed compared to their sector so far this year.